Carregant...

Electrophysiological Basis for the Antiarrhythmic Actions of Ranolazine

Ranolazine is an FDA-approved anti-anginal agent. Experimental and clinical studies have shown that ranolazine has anti-arrhythmic effects in both ventricles and atria. In the ventricles, ranolazine can suppress arrhythmias associated with acute coronary syndrome, long QT, heart failure, ischemia, a...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Antzelevitch, Charles, Burashnikov, Alexander, Sicouri, Serge, Belardinelli, Luiz
Format: Artigo
Idioma:Inglês
Publicat: 2011
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3131428/
https://ncbi.nlm.nih.gov/pubmed/21421082
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.hrthm.2011.03.045
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!